3-Methyladenine can depress drug efflux transporters via blocking the PI3K–AKT–mTOR pathway thus sensitizing MDR cancer to chemotherapy

References

• American Cancer Society, Inc. Cancer facts and figures. American Cancer Society 2012;500812:1–8
   Google Scholar
• Wang J, Pursell NW, Samson ME, et al. Potential advantages of CUDC-101, a multi-targeted HDAC, EGFR, and HER2 inhibitor, in treating, drug resistance and preventing cancer cell migration and invasion. Mol Cancer Ther 2013;12:925–36
   Google Scholar
• Nature America Inc. Cancer multidrug resistance: progress in understanding the molecular basis of drug resistance in cancer promises more effective treatments. Nat Biotechnol 2000;18(Suppl):IT18–20
   PubMedGoogle Scholar
• Che XF, Nakajima Y, Sumizawa T, et al. Reversal of P-glycoprotein mediated multidrug resistance by a newly synthesized 1,4-benzothiazipine derivative, JTV-519. Cancer Lett 2002;187:111–19
   PubMed Web of Science ®Google Scholar
• Morschhauser J, Barker KS, Liu TT, et al. The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog 2007;3:e164:1603–16
   Google Scholar
• Masayuki N, Akio E, Nobuyoshi N, et al. Clinical significance of multi-drug resistance associated protein and P-glycoprotein in patients with bladder cancer. J Urol 1997;157:1260–5
   PubMed Web of Science ®Google Scholar
• Zou Z, Wu L, Ding H, et al. MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 1-mediated autophagy. J Biol Chem 2012;287:4148–56
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615–27
   PubMed Web of Science ®Google Scholar
• Michael D. The human ATP-binding cassette (ABC) transporter superfamily. National Library of Medicine (US). Bethesda (MD): NCBI; 2002
   Google Scholar
• Zhu H, Wu H, Liu X, et al. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol 2008;76:582–8
   PubMed Web of Science ®Google Scholar
• Natalya SP, Mariya IM, Alya GV, et al. Silencing activity of 20-O-methyl modified anti-MDR1 siRNAs with mismatches in the central part of the duplexes. Fed Eur Biochem Soc 2011;85:2352–6
   Google Scholar
• Florie B, Richard VL, Annemart K, et al. In vivo knock-down of multidrug resistance transporters ABCC1 and ABCC2 by AAV-delivered shRNAs and by artificial miRNAs. J RNAi Gene Silencing 2011;7:434–42
   PubMedGoogle Scholar
• Piet B, Raymond E, Marcel K, Jan W. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000;92:1295–1302
   PubMed Web of Science ®Google Scholar
• Wu YT, Tan HL, Shui G, et al. Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class i and iii phosphoinositide 3-kinase. J Biol Chem 2010;285:10850–61
   PubMed Web of Science ®Google Scholar
• Navaratnarajah P, Steele BL, Redinbo MR, Thompson NL. Rifampicin-independent interactions between the pregnane X receptor ligand binding domain and peptide fragments of coactivator and corepressor proteins. Biochemistry 2012:51:19−31
   PubMed Web of Science ®Google Scholar
• Rodrigues AS, Dinis J, Gromicho M, et al. Genomics and cancer drug resistance. Curr Pharm Biotechnol 2012;13:651–73
   PubMed Web of Science ®Google Scholar
• Takakuwa O, Oguri T, Ozasa H, et al. Over-expression of MDR1 in amrubicinol-resistant lung cancer cells. Cancer Chemother Pharmacol 2011;68:669–76
   PubMed Web of Science ®Google Scholar
• Wang H, Chen XP, Qiu FZ. Overcoming multi-drug resistance by anti-MDR1 ribozyme. World J Gastroenterol 2003;9:1444–9
   PubMed Web of Science ®Google Scholar
• Braga F, Ayres-Saraiva D, Gattass CR, Capella MAM. Oleanolic acid inhibits the activity of the multidrug resistance protein ABCC1 (MRP1) but not of the ABCB1 (P-glycoprotein): possible use in cancer chemotherapy. Cancer Lett 2007;248:147–52
   PubMed Web of Science ®Google Scholar
• Shishido Y, Ueno S, Yamazaki R, et al. ABCG2 inhibitor YHO-13351 sensitizes cancer stem/initiating-like side population cells to irinotecan. Anticancer Res 2013;33:1379–86
   PubMed Web of Science ®Google Scholar
• Peng H, Qi J, Dong Z, Zhang JT. Dynamic vs static ABCG2 inhibitors to sensitize drug resistant cancer cells. PLoS One 2010;5:1–10
   Web of Science ®Google Scholar
• Carpenter C, Auger K, Chanudhuri M, et al. Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the 85-kDa subunit. J Biol Chem 1993;268:9478–83
   PubMed Web of Science ®Google Scholar
• Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Ann Rev Biochem 1998;67:481–507
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Waterfield MD. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 1999;253:239–54
   PubMed Web of Science ®Google Scholar
• Jimenez C, Hernandez C, Pimentel B. The p85 regulatory subunit controls sequential activation of phosphoinositide 3-kinase by Tyr kinases and Ras. J Biol Chem 2002;277:41556–62
   PubMed Web of Science ®Google Scholar
• Philp AJ, Campbell IG, Leet C. The phosphatidylinositol 3′-kinase p85{alpha} gene is an oncogene in human ovarian and colon tumors. Cancer Res 2001;61:7426–9
   PubMed Web of Science ®Google Scholar
• Khaleghpour K, Li Y, Banville D. Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma. Carcinogenesis 2004;25:241–8
   PubMed Web of Science ®Google Scholar
• Shao J, Evers BM, Sheng H. Roles of phosphatidylinositol 3′-kinase and mammalian target of rapamycin/p70 ribosomal protein S6 kinase in K-Ras-mediated transformation of intestinal epithelial cells. Cancer Res 2004;64:229–35
   PubMed Web of Science ®Google Scholar
• Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006;95:1148–54
   PubMed Web of Science ®Google Scholar
• Urbano A, Gorgun G, Foss F. Mechanisms of apoptosis by the tyrphostin AG957 in hematopoietic cells. Biochem Pharmacol 2002;63:689–92
   PubMed Web of Science ®Google Scholar
• Holmes D. PI3K pathway inhibitors approach junction. Nat Rev Drug Discov 2011;10:563–4
   PubMed Web of Science ®Google Scholar
• Simon M, Arkadiusz O, Olga P, Poger LW. Finding a fitting shoes for cinderella: searching for a autophagy inhibitor. Autophagy 2010;6:805–7
   PubMed Web of Science ®Google Scholar